Dr. Karen Jacobson is an Assistant Professor of Medicine in the Section of Infectious Diseases, Boston University School of Medicine, with a secondary appointment in the Department of Epidemiology, Boston University School of Public Health. Dr. Jacobson’s research focuses on the epidemiology of drug resistant tuberculosis, including identification of social, biological, and economic determinants of and risk factors for drug resistance and approaches for improving TB outcomes in resource-limited settings. Dr. Jacobson has established a highly productive collaboration with researchers at Stellenbosch University in Cape Town, South Africa, investigating the drivers of drug resistance in the Western Cape Province of South Africa and working to identify potentially modifiable factors.
- Assistant Professor, Epidemiology, Boston University School of Public Health
- Johns Hopkins University School of Medicine, MD
- Harvard School of Public Health, MPH
- Yale University, BS
- Published on 4/1/2018
Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr. 2018 Apr 01; 77(4):405-412. PMID: 29239900.
- Published on 2/19/2018
Brooks-Pollock E, Jacobson KR. Rethinking tuberculosis control by targeting previously treated individuals. Lancet Glob Health. 2018 Apr; 6(4):e361-e362. PMID: 29472017.
- Published on 10/15/2017
Farhat MR, Jacobson KR, Franke MF, Kaur D, Murray M, Mitnick CD. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clin Infect Dis. 2017 Oct 15; 65(8):1364-1370. PMID: 29017248.
- Published on 6/1/2017
Jacobson KR, Barnard M, Kleinman MB, Streicher EM, Ragan EJ, White LF, Shapira O, Dolby T, Simpson J, Scott L, Stevens W, van Helden PD, Van Rie A, Warren RM. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017 Jun 01; 64(11):1502-1508. PMID: 28199520.
- Published on 2/7/2017
Jacobson KR. Tuberculosis. Ann Intern Med. 2017 Feb 07; 166(3):ITC17-ITC32. PMID: 28166561.
- Published on 9/1/2016
Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M. Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med. 2016 Sep 01; 194(5):621-30. PMID: 26910495.
- Published on 1/13/2016
Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016 Mar; 54(3):727-33. PMID: 26763957.
- Published on 4/1/2015
Jacobson KR, Sabin LL. Scaling up multidrug-resistant tuberculosis care in China. Lancet Glob Health. 2015 Apr; 3(4):e183-4. PMID: 25794667.
- Published on 3/1/2015
Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis. 2015 Mar; 19(3):339-41. PMID: 25686144.
- Published on 12/13/2013
Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, Warren RM, Jacobson KR. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study. PLoS One. 2013; 8(12):e83480. PMID: 24349518.
View 9 more publications: View full profile at BUMC